Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

[1]  M. Pirisi,et al.  Post-meal coagulation activation in diabetes mellitus: the effect of acarbose , 1996, Diabetologia.

[2]  F. Cambien,et al.  Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes , 1989, Diabetologia.

[3]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[4]  Lawrence A Leiter,et al.  Acarbose in the treatment of elderly patients with type 2 diabetes. , 2003, Diabetes research and clinical practice.

[5]  J. Rosenthal,et al.  Effects on Blood Pressure of the α-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus , 2002 .

[6]  J. Manson,et al.  A prospective study of obesity and risk of coronary heart disease among diabetic women. , 2002, Diabetes care.

[7]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[8]  H. Laube.  Acarbose: An update of its therapeutic use in diabetes treatment , 2002 .

[9]  H. Lebovitz,et al.  Effect of the postprandial state on nontraditional risk factors. , 2001, The American journal of cardiology.

[10]  G. Mertes.  Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. , 2001, Diabetes research and clinical practice.

[11]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[12]  M. Hanefeld,et al.  Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. , 2000, Diabetes care.

[13]  S. Yusuf,et al.  Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.

[14]  A. Ceriello.  The post‐prandial state and cardiovascular disease: relevance to diabetes mellitus , 2000, Diabetes/metabolism research and reviews.

[15]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[16]  D. Heim,et al.  Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. , 1999, Diabetes, nutrition & metabolism.

[17]  R. Holman,et al.  Acarbose Maintains Glycaemic Control in Diet Treated Type 2 Diabetes , 1999 .

[18]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[19]  武井泉,et al.  United Kingdom Prospective Diabetes Study (UKPDS) , 1999 .

[20]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[21]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[22]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[23]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[24]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[25]  E. Barrett-Connor,et al.  Isolated Postchallenge Hyperglycemia and the Risk of Fatal Cardiovascular Disease in Older Women and Men: The Rancho Bernardo Study , 1998, Diabetes Care.

[26]  M. Noritake,et al.  Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. , 1998, Diabetes research and clinical practice.

[27]  R. Kawamori.  Asymptomatic hyperglycaemia and early atherosclerotic changes. , 1998, Diabetes research and clinical practice.

[28]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[29]  V. Salomaa,et al.  Impact of Diabetes on Mortality After the First Myocardial Infarction , 1998, Diabetes Care.

[30]  M. Spengler,et al.  Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. , 1997, The American journal of medicine.

[31]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[32]  M. Hanefeld,et al.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.

[33]  W. Puls.  Pharmacology of Glucosidase Inhibitors , 1996 .

[34]  S. Ross,et al.  The Efficacy of Acarbose in the Treatment of Patients with NonInsulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical Trial , 1994, Annals of Internal Medicine.

[35]  J. A. Hunt,et al.  The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus , 1994 .

[36]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[37]  M. Laakso,et al.  Diabetes and atherosclerosis: an epidemiologic view. , 1987, Diabetes/metabolism reviews.